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Objectives
• To determine the pharmacodynamic proﬁle of serum total
testosterone and luteinizing hormone (LH) levels in men
with secondary hypogonadism after initial and chronic daily
oral doses of enclomiphene citrate vs transdermal
testosterone.
• To determine the eﬀects of daily oral doses of enclomiphene
citrate in comparison with transdermal testosterone on
other hormones and markers in men with secondary
hypogonadism.
Patients and Methods
• This was a randomized, single-blind, two-centre, phase II
study to evaluate the eﬀects of three diﬀerent doses of
enclomiphene citrate (6.25, 12.5 and 25 mg) vs transdermal
testosterone on 24-h LH and total testosterone in otherwise
normal healthy men with secondary hypogonadism.
• Forty-eight men were enrolled in the trial (the
intent-to-treat population), but four men had testosterone
levels >350 ng/dL at baseline.
Forty-four men completed the study per protocol.
All subjects enrolled in this trial had serum total
testosterone in the low range (<350 ng/dL) and
had low to normal LH (<12 IU/L) on at least two
occasions.
• Total testosterone and LH levels were assessed each hour for
24 h to examine the eﬀects at each of three treatment doses
of enclomiphene citrate vs a standard dose (5 g) of
transdermal testosterone. In the initial proﬁle, total
testosterone and LH were determined in a naïve population
after a single initial oral or transdermal treatment (day 1).
This was contrasted to that seen after 6 weeks of continuous
daily oral or transdermal treatment (day 42).
• The pharmacokinetics of enclomiphene citrate were
assessed in a select subpopulation.
• Serum samples were obtained over the course of the study
to determine the levels of various hormones and lipids.
Results
• After 6 weeks of continuous use, the mean (SD)
concentration of total testosterone at day 42 was 604 (160)
ng/dL for men taking the highest dose of enclomiphene
citrate (enclomiphene citrate, 25 mg daily) and 500 (278)
ng in those men treated with transdermal testosterone.
These values were higher
than day 1 values but not diﬀerent from each other
(P = 0.23, t-test).
• All three doses of enclomiphene citrate increased the
testosterone concentration at time 0 of each 24-h sampling
period, and the mean, maximum, minimum and range of
testosterone concentrations over the 24-h sampling period.
Transdermal testosterone also raised total testosterone,
albeit with more variability, and with suppressed LH levels.
• The patterns of total testosterone over the 24-h period after
6 weeks of dosing could be ﬁt to a nonlinear function with
morning elevations, mid-day troughs, and rising night-time
levels.
• Enclomiphene citrate and transdermal testosterone
increased levels of total testosterone within 2 weeks, but
they had opposite eﬀects on FSH and LH.
• Treatment with enclomiphene citrate did not signiﬁcantly
aﬀect levels of thyroid-stimulating hormone,
adenocorticotropic hormone, cortisol, lipids or bone
markers. Both transdermal testosterone and enclomiphene
citrate decreased insulin-like growth factor-1 levels (P <
0.05) but suppression was greater in the enclomiphene
citrate groups.
Conclusions
• Enclomiphene citrate increased serum LH and total
testosterone; however, there was not a temporal
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association between the peak drug levels and the
maximum concentration levels of LH or total
testosterone.
• Enclomiphene citrate consistently increased serum total
testosterone into the normal range and increased LH and
FSH above the normal range. The eﬀects on LH and total
testosterone persisted for at least 1 week after stopping
treatment.
Keywords
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Introduction
Clomiphene citrate is approved by the Federal Drug
Administration (FDA) and is widely used in women for
induction of ovulation. Clomiphene citrate has been used
oﬀ-label to increase LH, FSH and testosterone levels in men
with idiopathic infertility and/or secondary hypogonadism;
however, it is not approved by the FDA for use in men.
Clomiphene citrate is a mixture of two diastereoisomers,
(cis)zuclomiphene citrate (38%) and (trans)enclomiphene
citrate (62%). The commercial name for enclomiphene citrate
is Androxal® [1]. Zuclomiphene is thought to cause some of
the side eﬀects that have been associated with clomiphene
citrate. By contrast, enclomiphene citrate is primarily
responsible for causing an increase in FSH and LH. One
example is men treated with exogenous testosterone, as such
treatment will relieve symptoms of secondary hypogonadism
but will not maintain or restore sperm production in the testes
[2,3].
Enclomiphene citrate is proposed for the treatment of
some men who have secondary hypogonadism, especially that
caused by dysfunctional, but reversible hypothalamus/pituitary
activity. These men present with low total testosterone and
low or inappropriately normal gonadotropin levels (LH
and FSH). Treatment of these men with an anti-oestrogen
or an aromatase inhibitor can increase gonadotropin and
testosterone levels; however, enclomiphene citrate is not
proposed for some forms of secondary hypogonadism such as
pituitary tumours, craniopharingiomas, haemochromatsis or
congenital GnRH deﬁciency.
The consequences of long-term secondary hypogonadism are
recognized health problems typically associated with ageing.
Indeed, secondary hypogonadism in men has been associated
with increased mortality, obesity, metabolic syndrome and/or
insulin resistance/type II diabetes [4–9]. Many studies have
shown that serum total and free testosterone in levels in obese
men are signiﬁcantly lower than aged-matched healthy male
controls [10]. The European Male Ageing Study showed
that obesity and ageing are risk factors for secondary
hypogonadism, while the prevalence of primary
hypogonadism is also linked to age [11].
Biological rhythms dominate reproductive hormone release in
both males and females. Classic experiments have shown that
the long-term, pulsatile administration of GnRH can induce
both puberty and fertility in GnRH-deﬁcient males who do
not initiate puberty spontaneously [12]. Patients with this
hypothalamic defect have helped elucidate the feedback
control of sex steroids at the level of the pituitary and the
hypothalamus and to identify additional defects [13–15]. At
the level of the hypothalamus, pituitary and testes there is a
clear rhythm that results in the testicular production of
testosterone in males, with healthy young men experiencing a
morning peak, a trough in the early evening, followed by a
gradual increase towards the morning peak [16]. In most
ageing men there is an overall decrease in testosterone levels
and a blunting in circadian androgen levels [17], perhaps
caused by the disruption of feedback and feed-forward control
mechanisms [18]. In addition, other factors may contribute, as
shown by the suppressive eﬀects of a standard glucose
tolerance test on serum testosterone levels [19]. Oestrogens
have also been shown to play a role in these feedback
processes in men [20].
The present study was undertaken in men with secondary
hypogonadism to better determine the proﬁle of serum
testosterone and LH after enclomiphene citrate administration
for 6 weeks in comparison to that for transdermal testosterone
treatment. In most studies with transdermal testosterone the
determination of serum levels of total testosterone constitutes
pharmacokinetics. In the present study, treatment with oral
enclomiphene citrate constitutes pharmacodynamics, i.e. an
eﬀect of the drug on the body.
In an early phase II study we evaluated the potential of oral
enclomiphene citrate to increase serum testosterone levels in
52 men with secondary hypogonadism [21]. Men who had low
total testosterone values at baseline had signiﬁcant increases in
serum total testosterone levels after 2 weeks of treatment with
enclomiphene citrate. The increase in total testosterone was
accompanied by increases in LH and FSH. A more recent
study provided evidence that enclomiphene citrate raises
testosterone levels in men with secondary hypogonadism and
also preserves or improves sperm counts [22,23]. This eﬀect
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was associated with increased endogenous levels of LH and
FSH. In the latter study, the randomized groups included
treatment with Testim®, a transdermal testosterone gel. In
contrast to the group receiving enclomiphene citrate, men
receiving Testim had a reduction in LH and FSH levels and in
sperm counts.
Patients and Methods
Patients
Forty-eight men were randomized to receive either: 6.25 mg
enclomiphene citrate (Androxal®, Repros Therapeutics Inc.,
Houston, TX, USA) daily (n = 16), 12.5 mg enclomiphene
citrate daily (n = 14), 25 mg enclomiphene citrate daily
(n = 16) or transdermal testosterone daily (AndroGel®, AbbVie
Inc., Chicago, IL, USA; n = 14). These men were deﬁned as the
intent-to treat (ITT) population. Four men (three in the
enclomiphene citrate 12.5 mg group and one man in the
enclomiphene citrate 25 mg group) were later found to have
testosterone levels >350 ng/dL at baseline. Forty-four subjects
completed the study per protocol (PP) and were deﬁned
as the PP population. The mean (SD) age and body mass index
(BMI) for the transdermal testosterone group(n = 13) were
53.3 (10.2) years and 31.5 (5.9) kg/m2, respectively. The mean
(SD) BMI for all men was 34.7 (7.2) kg/m2. There was no
signiﬁcant diﬀerence in age or BMI among the treatment
groups.
Laboratories
All hormone assays and blood chemistries were performed by
a central laboratory (Cetero Research, Houston, TX, USA).
Total testosterone, estradiol, dihydrotestosterone, LH, FSH,
IGF-1 and thyroid-stimulating hormone (TSH) were
determined by immunoassay. Others variables were
determined by standard laboratory methods. Analytical
procedures to determine concentrations of enclomiphene
citrate in human semen were performed at Cetero Research.
Serum triglycerides, total and high and low density lipoprotein
cholesterol levels were assayed using an ADVIA® 1650/2400
Chemistry system. Serum osteocalcin was assayed using an
ELISA kit (ALPCO Diagnostics).
Protocol
The present study was a randomized, single-blind, phase II,
four-arm study with a 6-week active dosing period. The
objectives were to assess LH and testosterone levels in men
with secondary hypogonadism. Two US sites participated in
the study between July and October 2011. Institutional review
board or independent ethics committee approvals were
obtained at each centre, all patients provided written
informed consent, and the study was conducted in
accordance with the Declaration of Helsinki and principles of
good clinical practice. Study participants were healthy males
18–65 years of age with morning testosterone levels
≤350 ng/dL and low or inappropriately normal LH levels and
normal screening chemistries. Subjects agreed to use a
condom or another form of contraception during the study.
Subjects with diabetes, hyperprolactinaemia, HIV, cataracts,
breast or prostate cancer, end-stage renal disease, cystic
ﬁbrosis, uncontrolled hypertension, abnormal haemoglobin
or heamatocrit, or subjects using medications known to
interfere with sex steroid synthesis or action were
excluded. The exclusion criteria also included the use of
testosterone <3 months before the study, the use of
clomiphene citrate in the past year, the use of spironolactone,
cimetidine, 5α-reductase inhibitors, hCG, oestrogen,
glucocorticoids, narcotics, anabolic steroids,
dehydroepiandrosterone or herbal hormone products,
and a PSA level >3.6 ng/mL or BMI >42 kg/m2.
The men in each of the four study arms were randomized to
one of three single-blind enclomiphene citrate doses or open
label transdermal testosterone. The doses of enclomiphene
citrate in the single-blind portion of the study were
enclomiphene citrate 6.25, 12.5 and 25 mg (Rainbow Gold
Products, Inc., Boaz, AL, USA). Capsules were supplied by
Repros Therapeutics. Subjects receiving enclomiphene
citrate were instructed to take one capsule of blinded
study medication between 7:00 h and 10:00 h every day.
Transdermal testosterone was applied as per the package
insert. Subjects were instructed to apply the gel at the same
time each day, and not to bathe or swim for 3–4 h after
application. At visit 1 (or week 2) subjects underwent
screening procedures, which included signing of the consent
form, a complete medical history, medication history, physical
examination, blood evaluation and a slit lamp eye examination
and visual acuity test. Eligible subjects underwent a 24-h
assessment of baseline total testosterone, LH and FSH (visit 2
or week 0). Blood samples were also collected to test for lipids
and hormones and subjects were asked to follow a normal
ad libitum diet. Subjects received a study medication kit,
containing a 2-week supply of study medication. Men in the
transdermal testosterone arm were instructed to apply the
gel at the same time every day and to schedule their oﬃce
visit ∼4 h after the time of application. Subjects in the
enclomiphene citrate arms returned for visits at 2 and 4 weeks
in the morning (before 09:00 h) for blood draws (before
10:00 h) to measure total testosterone, FSH, LH and trough
levels of the study drug. At 6 weeks, subjects underwent a 24-h
assessment of total testosterone and LH. During this time
blood was also drawn for a pharmacokinetic assessment of
serum enclomiphene citrate levels at 0, 1, 2, 3, 4, 6, 8, 12, 16
and 24 h after a single dose of enclomiphene citrate (6.25,
12.5, 25 mg enclomiphene citrate). Subjects returned at 7
weeks for a ﬁnal blood draw after a 1-week washout (before
10:00 h).
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Statistical Analysis
Statistical analysis of the primary eﬃcacy variable was the
change between day 1 and day 42 in the 24-h mean
testosterone and LH levels. An overall comparison among the
four treatment groups was performed using ANOVA or the
Kruskal–Wallis test. The secondary eﬃcacy variables were the
changes in total testosterone, LH and FSH over the course
of the study. Changes in lipids and other hormones were
assessed between the baseline and week 6. An analysis of
pharmacokinetics for the enclomiphene citrate arms also was
performed based on enclomiphene citrate concentrations in
serum at 0, 1,2, 3, 4, 8, 12, 16 and 24 h drawn during week 6.
Summaries for quantitative variables include the sample size
and the mean, median, SD, minimum and maximum values.
Summaries for categorical variables include the number and
percent of patients for each outcome. Diﬀerences between
groups were determined by t-test, paired t-test or
Mann–Whitney–Wilcoxin (MWW) test. A regression analysis
was conducted to determine whether morning testosterone
was predictive of the mean, minimum and maximum
concentrations of total testosterone (CTTmean, CTTmin and CTTmax,
respectively) at various time points.
Results
The present study was intended to be a study in men with
secondary hypogonadism.We screened men with two
morning total testosterone measurements <350 ng/dL
(<10.4 nmol/L) and an appropriate LH level (<12 IU/L).
Forty-eight men qualiﬁed and were deﬁned as the ITT
population. Testosterone concentration at time 0 of each 24-h
sampling period (CTT0h) values were determined before the
drug was administered (i.e. the initial pharmacodynamics).
Four subjects were removed from the analysis because their
total testosterone levels were >350 ng/dL. These men were
included for hormone and safety considerations. The
remaining 44 men constituted the per protocol (PP)
population.
Characteristics of the study arms are shown in Table 1. There
were no diﬀerences between groups at baseline, and total
testosterone levels increased in all treatment arms compared
with pre-treatment levels. After daily treatment for 6 weeks,
diﬀerences among treatment groups were signiﬁcant
according to ANOVA. These observations were true whether
the data were recorded as CTT0h, CTTmean, CTTmax, CTTmin values
or as the range of total testosterone concentration (CTTrange).
Increases from day 1 were signiﬁcant for the 6.25 mg
enclomiphene citrate group (P = 0.007, paired t-test), the
25 mg enclomiphene citrate group (P = 1 × 10−5, paired t-test)
and for the transdermal testosterone group (P = 0.014
signed-rank test). The 6.25-mg and 25-mg enclomiphene
citrate groups had an increase in serum LH concentration
from pre-treatment levels, whereas transdermal testosterone Ta
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decreased the mean serum LH level. These changes were
signiﬁcant for enclomiphene citrate 6.25 mg (P = 0.023,
paired t-test), enclomiphene citrate 25 mg (P = 7 × 10−4, paired
t-test) and for transdermal testosterone (P = 1 × 10−4, paired
t-test). Changes in LH paralleled the increases in total
testosterone in kind if not quantity for the enclomiphene
citrate groups.
The results of the two 24-h pharmacodynamic studies
provided useful comparisons between treatment with
transdermal testosterone and enclomiphene citrate (Fig. 1).
We observed an increase in concentration of testosterone in
all treatment groups after 6 weeks of treatment in the PP
population. On day 1 there were no diﬀerences between the
groups in terms of mean CTT0h, or their average CTTmean, CmaxTT,
CTTmin, or CTTrange values. On day 1 transdermal testosterone
raised the CTTmean and CTTmax, although those increases were
not signiﬁcant among groups; probably because of the high
variation in the mean values in the subjects who were treated
with transdermal testosterone.
Fig. 1 Effect of enclomiphene citrate on the pharmacodynamics of serum total testosterone compared with transdermal testosterone. The effects of
various treatments are seen over 24-h period and compared between an initial dose and a dose given following 6 weeks of continuous treatment.
Men with AIHH were treated with (A) transdermal testosterone according to label instructions initially (open triangles and dashed line) and after daily
dosing (filled triangles and solid line); (B) enclomiphene citrate 6.25 mg initially (open diamonds and dashed line) and after daily oral dosing (filled
diamond and solid line); (C) enclomiphene citrate 12.5 mg initially (open circles and dashed line) and after daily oral dosing (filled circles and solid
line); and (D) enclomiphene citrate 25 mg initially (open squares and dashed line) and after daily oral dosing (filled squares and solid line). A second
order polynomial is fitted to the data points and the R2 value is given next to the line. TT, total testosterone.
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Mean testosterone levels increased in all treatment groups at 6
weeks. Transdermal testosterone was associated with a wider
range of total testosterone values than we found for the
enclomiphene citrate groups, as shown in Table 1. For
example, after 6 weeks on treatment, the mean ± SD CTTrange
was 590 ± 465 ng/dL (20.5 ± 16.1 nmol/L) for the subjects in
the transdermal testosterone group and 314 ± 65 ng/dL (10.9
± 2.2 nmol/L) for subjects in the enclomiphene citrate 25 mg
group. The coeﬃcients of variation of those two groups were
79 and 21%, respectively.We speculate that the wide variation
of total testosterone in the topical treatment group may result
from application issues (i.e. rushing application, not applying a
full dose by leaving gel in vial, washing dose away from hands
before fully absorbed), from skin thickness diﬀerences
between patients, or from the timing of application.
Figure 2 shows the number of outlier values associated with
each treatment during the 24-h sampling. Outlier values are
those serum total testosterone values below the 300 ng/dL
(10.4 nmol/L) or above the 1000 ng/dL (34.7 nmol/L) level
found within each 24-h study sampling for the PP population.
When we looked at the eﬀects of each of the treatments before
and after the 6-week treatment regimen, it was determined
that there were many fewer values below 300 ng/dL before
treatment, as expected, but after treatment there was a higher
percentage of morning total testosterone values in the
300–1000 ng/dL range. There was a clear shift in the morning
total testosterone values from <300 ng/dL to the
300–1000 ng/dL range for the enclomiphene citrate 25 mg
group. This shift also appeared to be dose-dependent for
enclomiphene citrate treatment. Transdermal testosterone
was found to have more outlier values, i.e. not in the
300–1000 ng/dL range. To further assess the eﬀects of each
treatment we evaluated the data in relation to responders
(Table 2).
After 6 weeks of enclomiphene citrate and transdermal
testosterone treatment, serum LH levels were altered in
opposite ways. All enclomiphene citrate dose groups were
found to have increased LH levels, whereas the transdermal
testosterone treatment arm had suppressed LH levels
(Fig. 3). There was considerable variability in LH values
hour-to-hour, probably because of the pulsatile nature of its
pituitary secretion. To discern a pulsatility pattern would
require that samples be drawn every 10 min for at least
4–6 h.
The pharmacokinetics of enclomiphene citrate after a single
enclomiphene citrate dose during week 6 are shown in Fig. 4
for a subset of the study population. The individual and
overall pharmacokinetic proﬁles showed essentially a rapid
rise of the drug in the serum with a CTTmax of 2–3 h, followed
by a loss that was typical of an apparent ﬁrst order process.
Calculations of the mean area under the curve (AUC)0–24h
show that the value for the 25 mg dose was ∼4.5 times and 7.5
times higher, respectively, than the values for the 12.5 and
6.25 mg doses. There was also evidence of an accumulation of
drug in the serum because serum levels did not return to
baseline 24 h after taking the drug. The pharmacokinetic
proﬁle of enclomiphene citrate did not match the serum LH
patterns, which ﬂuctuated considerably across the 24-h
observation period but were uniformly elevated.
Fig. 2 Outlier values of serum total testosterone found during the 24-h
pharmacodynamic studies' PP population. The distribution of morning TT
values determined during the two pharmacodynamic studies which were
conducted before and after 6 weeks of continuous treatment. Subjects
randomized to the transdermal testosterone (Gel) group are shown by
solid bars; lightly stippled bars represent the enclomiphene citrate
6.25 mg group, darkly stippled bars represent the enclomiphene citrate
12.5 mg group and the vertical lined bars represent the enclomiphene
citrate 25 mg group. TT, total testosterone.
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Table 2 Graded responder analysis: PP population.
Transdermal
testosterone
Enclomiphene
citrate 25 mg
Enclomiphene
citrate 12.5 mg
Enclomiphene
citrate 6.25 mg
N = 13 N = 12 n = 7 n = 12
Any increase in total testosterone, n (%) 13 (100) 12 (100) 7 (100) 9 (75)
CTTmean >300 ng/dL, n (%) 11 (85) 12 (100) 5 (71) 7 (58)
CTTmean >350 ng/dL, n (%) 11 (85) 12 (100) 4 (57) 6 (50)
CTTmean >400 ng/dL, n (%) 10 (77) 12 (100) 3 (43) 5 (42)
CTTmean >500 ng/dL, n (%) 6 (46) 8 (67) 3 (43) 3 (25)
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One of our objectives was to determine whether there were
clear relationships between the various ways of measuring
serum total testosterone when using enclomiphene citrate as a
treatment.We compared the various values of serum total
testosterone after both a single acute dose and a dose taken
after 6 weeks of treatment, i.e. in a steady state.We were most
interested in whether, at steady state, there was a clear
relationship with serum total testosterone over time.We
further explored the relationship between a morning serum
total testosterone (i.e. CTT0h) value and the average serum total
testosterone value returned over 24 h. This relationship was
shown for the enclomiphene citrate 25 mg group.When we
compared CTT0h with CTTmean values for each subject, we
determined that there was a clear linear relationship between
the values (Fig. 5). For the men treated for 6 weeks, the linear
relationship was strong (R = 0.93), had a slope near unity
(1.025) and an intercept that was low (4.96 ng/dL or
0.17 nmol/L) compared with the physiological range
Fig. 3 Effect of enclomiphene citrate on the pharmacodynamics of serum LH compared with transdermal testosterone. The effects of various treatments
are seen over 24 h and compared between an initial dose and a dose given after 6 weeks of continuous treatment. Men with AIHH were treated with
(A) transdermal testosterone according to label instructions initially (open triangles and dashed line) and after daily dosing (filled triangles and solid
line); (B) enclomiphene citrate 6.25 mg initially (open diamonds and dashed line) and after daily oral dosing (filled diamond and solid line); (C)
enclomiphene citrate 12.5 mg initially (open circles and dashed line) and after daily oral dosing (filled circles and solid line); and (D) enclomiphene
citrate 25 mg initially (open squares and dashed line) and after daily oral dosing (filled squares and solid line.) A second order polynomial is fitted to
the data points and the R2 value is given next to the line.
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interrogated (100–900 ng/dL or 3.5–31.2 nmol/L).When we
compared the other serum total testosterone measures with
CTT0h,we determined strong correlations for CTTmax, CTTmin and
CTTrange as well (Table 3). The relationships were not as strong
after a single dose of enclomiphene citrate (data not shown)
and transdermal testosterone showed a poorer relationship.
The time course of the serum total testosterone over the entire
study is shown in Fig. 6 for the ITT population. There was
no diﬀerence among the groups at the ﬁrst or second
qualifying visits (week 2, P = 0.74, ANOVA; week 0, P = 0.23,
Kruskal–Wallis test, respectively). Total testosterone levels
after 2 weeks of treatment for the two highest doses of
enclomiphene citrate and transdermal testosterone were
similar. Total testosterone levels increased signiﬁcantly in all
groups at 2 weeks when compared with baseline, but the
Fig. 4 Pharmacokinetics of serum enclomiphene citrate. After 6 weeks of
continuous oral dosing at various dosages of enclomiphene citrate,
serum samples were obtained at various time points for the assessment
of serum drug levels. The levels of serum enclomiphene citrate are given
for subjects taking 6.25 mg (filled diamonds), 12.5 mg (filled circles), and
25 mg (filled squares) of study drug.
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Fig. 5 Relationship in morning total testosterone concentration to average
total testosterone concentration for the enclomiphene citrate 25 mg
group. An example of the relationship between a morning total
testosterone value and the average total testosterone value over a 24-h
period is given. Subjects were all men with AIHH who had been treated
for 6 weeks with enclomiphene citrate and the pharmacodynamics of
their total testosterone was determined (pharmacodynamic study part 2);
thus, they were assessed for total testosterone every hour for 24 h and the
mean hourly total testosterone was determined. TT, total testosterone.
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Table 3 Correlation coefficients comparing various assessments of serum
total testosterone during the final 24-h pharmacodynamic study: PP
population.
Treatment n Correlation coefficient
CTT0h vs
CTTmean
CTT0h vs
CTTmax
CTT0h vs
CTTmin
Transdermal testosterone 13 0.56 0.58 0.62
Enclomiphene citrate 25 mg 12 0.93 0.86 0.87
Enclomiphene citrate 12.5 mg 7 0.82 0.76 0.90
Enclomiphene citrate 6.25 mg 12 0.87 0.82 0.82
Fig. 6 Time course of effects on serum total testosterone. Figure shows the
levels of serum total testosterone found before and after treatment with
daily doses of enclomiphene citrate 6.25 mg (open squares),
enclomiphene citrate 12.5 mg (green squares), enclomiphene citrate
25 mg (red squares) or transdermal testosterone (orange triangles). TT,
total testosterone.
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serum total testosterone for the transdermal testosterone
group and the enclomiphene citrate 25 mg group were
signiﬁcantly higher than for the enclomiphene citrate 6.25 mg
group (P = 0.025 and P = 0.016, t-test). A steady state, deﬁned
here by serum total testosterone values >400 ng/dL, appeared
after 4 weeks of treatment with both agents. There were no
signiﬁcant changes from week 2 to 4 or from week 4 to 6 for
any group.
Seven days after cessation of treatment, total testosterone
levels in men receiving enclomiphene citrate 25 mg were
higher than those in men receiving enclomiphene citrate
12.5 mg (P = 0.012, t-test), and total testosterone levels in the
enclomiphene citrate 12.5 mg group were higher than those
in the men on transdermal testosterone (P = 0.003, t-test).
There was no signiﬁcant diﬀerence between the serum total
testosterone for the groups on any of the enclomiphene citrate
doses over the last 7 days (at least P > 0.4 for all groups,
t-test). The greatest preservation of serum total testosterone
was found in the enclomiphene citrate 25 mg group, in which
it was found to be slightly increased.
The time course of LH over the study is shown in Fig. 7.
Levels were similar at the ﬁrst and second baseline visits
(weeks 2, P = 0.10, ANOVA; week 0, P = 0.16, Kruskal–Wallis
test, respectively). The increases in serum LH during the ﬁrst 2
weeks of treatment were similar in the enclomiphene citrate
groups, but transdermal testosterone signiﬁcantly decreased
the mean LH level (P = 0.026, t-test). The changes attributable
to treatment (i.e. between week 2 and week 4) were signiﬁcant
for all four groups including the enclomiphene citrate
6.25 mg group; however, the serum LH for the transdermal
testosterone group was the lowest and the 12.5 and
enclomiphene citrate 25 mg dose groups were not signiﬁcantly
diﬀerent. Mean serum LH values were >6 IU/L after 4 weeks
of treatment with the two higher doses of enclomiphene
citrate. There were no signiﬁcant changes from week 2 to 4 or
from week 4 to 6 for any group (P > 0.14, for any change in
any group, t-test). Seven days after cessation of treatment,
mean LH levels for men receiving enclomiphene citrate
25 mg were higher than those for men receiving enclomiphene
citrate 6.25 mg (P = 0.001, MWW test), 12.5 mg (P = 0.001,
MWW test) or transdermal testosterone (P < 0.001, MWW
test). The mean LH concentration for men on transdermal
testosterone increased signiﬁcantly (P = 0.007, t-test) over this
time period, and it was similar to baseline values; however,
mean LH concentrations in men on enclomiphene citrate
remained signiﬁcantly higher than baseline values. The serum
LH levels remained elevated over the 7 days after stopping
enclomiphene citrate: there was no signiﬁcant diﬀerence for
the serum LH for the enclomiphene citrate doses over that
time period (at least P > 0.4 for all groups, t-test). Each of the
four treatments established new plateau values. Thus, 7 days
after the last dose, serum LH for enclomiphene citrate
25 mg was higher than that for enclomiphene citrate
12.5 mg (P = 0.025, t-test), for enclomiphene citrate 6.25 mg
(P = 0.006, t-test), and for transdermal testosterone (P < 0.001,
t-test).
The decrease in FSH associated with transdermal testosterone
was signiﬁcant (P = 2 × 10−4, paired t-test). The course of the
eﬀect is shown in Fig. 8. Before initial treatment at visit 2
(week 0), subjects did not diﬀer in terms of FSH (P = 0.32,
Kruskal–Wallis test). Treatment with enclomiphene citrate
increased FSH levels within 2 weeks for the 12.5 mg (P =
0.026, t-test) and the 25 mg group (P = 0.006, MWW test).
Transdermal testosterone reduced serum FSH at 2, 4
and 6 weeks. FSH levels continued to rise in men in the
enclomiphene citrate 25 mg group. At week 4, serum FSH
levels were higher in the enclomiphene citrate 25 mg group
than in the enclomiphene citrate 12.5 mg (P = 0.010, MWW
test) or the enclomiphene citrate 6.25 mg groups (P = 0.004,
MWW test). This pattern was maintained at week 6. The two
lower doses appeared to reach a plateau which was lower than
the 25 mg dose by the 4-week point. Although serum FSH at 2
weeks with the 25 mg dose of enclomiphene citrate was clearly
higher, no treatment group showed a signiﬁcant change in
serum FSH from weeks 2 to 4 or from weeks 4 to 6 (at least
P > 0.51 for all groups, t-test). The increase in FSH was
signiﬁcant for the 25 mg dose (P = 0.006, signed-rank test) and
Fig. 7 Time course of effects on LH. The levels of serum LH are shown
before and after daily treatment with enclomiphene citrate 6.25 mg
(open squares), enclomiphene citrate 12.5 mg (green squares),
enclomiphene citrate 25 mg (red squares) or transdermal testosterone
(orange triangles).
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for the 12.5 mg dose (P = 0.022, signed-rank test) but not for
the 6.25 mg dose (P = 0.15, paired t-test).
We also investigated the eﬀects of enclomiphene citrate on
adenocorticotropic hormone (ACTH), cortisol, TSH, IGF-1
and lipids, by comparing these before treatment (baseline) and
after 6 weeks of dosing. As shown in Table 4, there were no
signiﬁcant diﬀerences at baseline among the treatment groups
except with regard to the bone marker carboxy-terminal
collagen, which was unaccountably higher in the transdermal
testosterone group.
We were unable to assess serum human growth hormone
(hGH) in our subjects for technical reasons but we were able
to measure its surrogate marker, IGF-1. Each treatment
lowered the level of IGF-1 in the serum of treated men
compared with the baseline values. As seen in Fig. 9, all
enclomiphene treatments lowered serum IGF-1 to
approximately the same extent and each was lower and
signiﬁcantly diﬀerent from the transdermal testosterone
treatment arm (for 6.25 mg, P = 0.008, for 12.5 mg, P = 0.004;
for 25 mg, P = 0.008; MWW test).
Discussion
In the present study, we characterized the LH and testosterone
levels at baseline and after 6 weeks dosing of enclomiphene
Fig. 8 Time course of effects on FSH. The levels of serum FSH are shown
before and after treatment with 6.25 mg enclomiphene citrate (open
squares), 12.5 mg enclomiphene citrate (grey squares), enclomiphene
citrate 25 mg (black squares) or transdermal testosterone (grey
triangles).
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citrate 6.25 mg/day, 12.5 mg/day and 25 mg/day and after daily
application of transdermal testosterone gel 5 g/day. Each dose
of enclomiphene citrate increased the mean concentration of
LH (CLHmean) and the CTTmean at 6 weeks.While transdermal
testosterone increased the CTTmean, it suppressed the CLHmean at
6 weeks.We have shown that a single, morning total
testosterone measurement is an accurate surrogate for
determining the eﬀect of enclomiphene citrate on
concentration of testosterone in men with secondary
hypogonadism. A single morning assessment of total
testosterone, CTT0h, predicts 24-h serum total testosterone
values CTTmean, as well as CTTmax and CTTmin and can, therefore,
be reliably used in monitoring the response of an individual to
treatment and for dose escalation for enclomiphene citrate.
This also ensures that a single morning value can predict the
lack of supraphysiological levels of total testosterone.
The greatest increase in LH was exhibited when doses were
escalated from 12.5 to 25 mg, but the 24-h average of total
testosterone only increased by 27%, suggesting a dose-limiting
eﬀect on the testosterone-producing Leydig cells of the testes,
and the inability of enclomiphene citrate to stimulate the
production of supernormal levels of testosterone. Additionally,
there was also an increase in FSH as has been shown
previously for clomiphene in healthy men [24]. Transdermal
testosterone, by contrast, signiﬁcantly suppressed LH after as
little as 2 weeks of administration. The relatively higher levels
of FSH, compared with those of LH, suggest that sperm count
was being stimulated.We have demonstrated this in another
study [23].
Comparison of testosterone levels stimulated by enclomiphene
citrate with those obtained by application of a transdermal
androgen reveals several signiﬁcant diﬀerences. Using
data obtained by 24-h sampling at week 6 of treatment,
transdermal testosterone caused greater variability in serum
testosterone levels (Fig. 1). A higher percentage of samples had
total testosterone values <300 ng/dL with transdermal
testosterone (50/305 [16.4%]) vs (131/287 [46%]) in the
enclomiphene citrate 6.25 mg group, (42/162 [26%]) in the
enclomiphene citrate 12.5 mg group and (0/272 [0%]) in the
enclomiphene citrate 25 mg group. Second, a higher
percentage of samples in the transdermal testosterone group
had testosterone levels >1000 ng/dL (17/305 [6%]) vs 0/287
[0%]) in the enclomiphene citrate 6.25 mg group, (0/162 [0%])
in the enclomiphene citrate 12.5 mg group and (2/272 [1%])
in the enclomiphene citrate 25 mg group. Finally, the CTTrange
was greater with transdermal testosterone (590 ± 465 ng/dL)
than for the enclomiphene citrate 12.5 mg and 25 mg groups
(246 ± 106 and 314 ± 65 ng/dL, respectively; P < 0.001).We
conclude that the use of enclomiphene citrate, especially at
25 mg, has many fewer outlier values.
The natural daily pattern of total testosterone in young men
would be a high morning level, a mid-day trough and a
night-time rise. This has not been observed in men >40 years
of age [25]. In the case of transdermal testosterone, the
increase in total testosterone was evident between the
pharmacodynamic studies parts 1 and 2 (Fig. 1A). This
increase was also seen for the enclomiphene citrate groups,
and most strongly for the 25 mg group (Fig. 1D). The
relationship between total testosterone and the time after
dosing was variable and there was a clear linear increase in
total testosterone over time, especially in the naïve men
where transdermal testosterone appeared to work early. As
noted, that pattern was variable among subjects. Although
all subjects took the study drug in the morning, the patterns
seen for enclomiphene citrate were best characterized by a
mid-day trough with relatively higher levels in the morning
and evening for each individual. All subjects in the
enclomiphene citrate arms (Fig. 1B–D) appeared to show
the natural daily pattern of ﬂuctuation as seen in young men.
The enclomiphene citrate pattern was a poor ﬁt for a linear
regression analysis, but ﬁt a second order polynomial
regression better for the 6.25 mg (R2 = 0.86), 12.5 mg
(R2 = 0.76) and the 25 mg enclomiphene citrate doses
(R2 = 0.63). The trough total testosterone for all
enclomiphene citrate doses occurred between 8 and 14 h
after dosing. It should be noted that this treatment was not
dose-dependent, therefore, this observation is interesting, but
not conclusive. The transdermal testosterone pattern was a
poor ﬁt to either a linear regression or a second order
polynomial (R2 = 0.14). The daily pattern for transdermal
testosterone was diﬀerent from that of the enclomiphene
citrate treatment. It would be premature to speculate
that enclomiphene citrate treatment restores the daily
testosterone rhythm that is typical of younger men. A much
larger study would be required to explore the phenomenon
we see here.
Fig. 9 Effect of 6 weeks of treatment on serum IGF-1. Red bars represent
pretreatment values, and green bars indicate levels after 6 weeks of
treatment.
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We investigated other pituitary hormones including ACTH,
TSH and IGF-I as surrogates for hGH.We also investigated
other hormones, lipids and chemistries for safety. The results
are shown in Table 4 and summarized above. In general,
enclomiphene citrate had few changes in these hormones and
markers, with the exception of IGF-1. IGF-1 is secreted by
the liver and is regulated in part by hGH levels; however
circulating levels also are dependent on the proteins that bind
IGF-1 in the circulation. IGF-1 levels were decreased in the
men in the enclomiphene citrate groups, but not in the
transdermal testosterone group, but the levels remained within
the normal physiological ranges.We are uncertain as to the
signiﬁcance of this observation. Testosterone treatment of men
with testosterone deﬁciency usually increases serum estradiol
levels, and may increase hGH and IGF-1 levels. Estrogen is
known to potentiate secretion of hGH and IGF-1 levels.
Enclomiphene citrate increases serum estradiol levels.We
suspect that the anti-estrogen eﬀects of enclomiphene citrate
are working at either the hypothalamic-pituitary level or
possibly on the liver to reduce IGF-1 levels. Unfortunately,
technical issues prevented the measurement of hGH levels in
the serum samples from these men. It would also be relevant
to know if enclomiphene citrate treatment aﬀects the
IGF-binding proteins.
A review of the response to the three doses of enclomiphene
citrate tested in the present study show that the 12.5 mg dose
produces minimal improvement in LH and testosterone
compared with the 6.25 mg dose, although the response seems
more reliable. The responder analysis suggests that the
12.5 mg dose is superior to the 6.25 mg dose in terms of
bringing men into the mid-normal range. The 25 mg dose
produces signiﬁcantly greater levels of LH than either of
the two lower doses, which we infer to be the primary
result of antagonism of the central oestrogen receptors by
enclomiphene citrate. This dose-dependent increase between
the 12.5 and 25 mg doses is also evidenced in the signiﬁcant
increase in the maximum concentration and AUC when the
dose was increased from 12.5 to 25 mg (data not shown). For
these reasons we posit that the 12.5- and 25-mg doses of
enclomiphene citrate warrant further clinical development.
Perhaps, the most signiﬁcant observation in the present study
was the restoration of normal levels and pattern of total
testosterone plus normal or elevated levels of LH, unlike
that seen with the exogenous testosterone treatment. The
persistence of serum total testosterone after discontinuation of
enclomiphene citrate 25 mg was in sharp contrast to those
men who had taken transdermal testosterone. In addition,
the eﬀect seen in men does not appear to be the result of
increasing serum testosterone, as transdermal testosterone
raised total testosterone to approximately the same extent as
the highest doses of enclomiphene citrate. The eﬀects were
most likely attributable to the eﬀects initiated through the
oestrogen antagonist properties of enclomiphene citrate or its
metabolite. Since this persistence or ‘legacy’ eﬀect, cannot be
attributable to the accumulation of enclomiphene citrate,
which is known to have a serum half-life of ∼7 h [26], we
believe that it may be the eﬀect of the anti-hormone on
a third factor, perhaps on one or more elements of the
hypothalamic-pituitary-gonadal axis. This persistence of
total testosterone after a drug holiday could be a practical
advantage for men who took enclomiphene citrate to increase
total testosterone because they would have some conﬁdence
that missing one or two dosing days would not mean that
their total testosterone would drop precipitously. This eﬀect is
distinct from other known testosterone replacement therapies
and could lead to an eventual intermittent dosing regimen
that could also address the development of tachyphylaxis.
This legacy eﬀect was also found for FSH and LH. It is
tempting to speculate that the eﬀect of daily administration of
an anti-oestrogen such as enclomiphene citrate results in the
restoration of the normal underlying LH and FSH patern that
has been lost in men with secondary hypogonadism.
In conclusion, enclomiphene citrate reverses the two hallmarks
of secondary hypogonadism, namely, low serum total
testosterone and low or inappropriately normal LH. There
is also an elevation of serum FSH. Enclomiphene citrate
treatment leads to a persistence of its total testosterone
elevating activity for at least 1 week after discontinuation by
maintaining LH. Transdermal testosterone raised total
testosterone but suppressed serum levels of LH and FSH. The
elevations of LH, FSH and testosterone in men taking
enclomiphene citrate provide mechanisms for the positive
eﬀects we have seen on sperm counts, and it contrasts with the
suppressive eﬀects of exogenous testosterone delivery systems
on sperm counts. The pharmacokinetics of enclomiphene
citrate over 24 h diﬀer from the LH and testosterone patterns,
emphasizing the likelihood that enclomiphene citrate aﬀects
biological mechanisms that persist after serum levels of
enclomiphene citrate fall. There appear to be few eﬀects of
enclomiphene citrate on other hormones, lipids, or bone
variables other than a decrease in IGF-1, suggesting that hGH
is inﬂuenced but not the other pituitary hormones assessed in
the present study. The cause of this latter eﬀect is uncertain,
but could be related to a decrease in hGH levels or to
anti-oestrogen eﬀects on the liver. These studies indicate that
enclomiphene citrate restores LH and testosterone levels, while
exogenous testosterone replacement can achieve testosterone
levels within the normal range, but it suppresses LH and FSH
levels and spermatogenesis.
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